Publications by authors named "Yu Yoshinaga"
Background: The loss of corneal epithelial stem cells from the limbus at the edge of the cornea has severe consequences for vision, with the pathological manifestations of a limbal stem-cell deficiency (LSCD) difficult to treat. Here, to the best of our knowledge, we report the world's first use of corneal epithelial cell sheets derived from human induced pluripotent stem cells (iPSCs) to treat LSCD.
Methods: This non-randomised, single-arm, clinical study involved four eyes of four patients with LSCD at the Department of Ophthalmology, Osaka University Hospital.
Article Synopsis
- The study reports a case of corneal endothelial damage in a 22-year-old man following neurosurgery where chlorhexidine gluconate (CG-A) was used for disinfection.
- After surgery, the patient experienced eye issues like swelling and corneal erosion, with initial improvements observed by day 14.
- However, endothelial cell density (ECD) significantly dropped over 168 days, indicating that CG formulations can cause long-term damage to corneal cells despite initial recovery.
When corneal epithelial stem cells residing in the corneal limbus become dysfunctional, called a limbal stem cell deficiency (LSCD), corneal transparency is decreased, causing severe vision loss. Transplantation of corneal epithelial cell sheets (CEPS) derived from stem cells, including induced pluripotent stem cells, is a promising treatment for LSCD. However, the potential effect of human leukocyte antigen (HLA) concordance on CEPS transplantation has not been addressed.
View Article and Find Full Text PDF